Judith López

@drbennisahmed @jcobaya69 EXCELENT SUMMARY 🙌

🔬 5 major obesity medicine updates from #ECO2026 — here’s what you need to know 🧵 1/ SURMOUNT-MAINTAIN — Zepbound works, but only if you stay on it. Full dose → maintained ALL weight loss Dropped to 5mg → regained ~12 lbs Switched to placebo → regained up to 43 lbs 67% of placebo patients needed rescue therapy 😳 2/ ATTAIN-MAINTAIN — Oral Foundayo (orforglipron) after Wegovy/Zepbound preserved most weight loss vs. placebo. Transition drugs are viable. 💊 3/ High-dose Wegovy 7.2mg — Early responders lost an average of 27.7% body weight by week 72. Early response = strong predictor of outcomes. 📈 4/ Wegovy PILL (oral semaglutide 25mg) — Early responders lost 21.6% body weight by week 64 vs. 2.7% placebo. An oral GLP-1 that actually works. 🙌 5/ Body composition data — ~84% of weight lost was fat mass. Visceral fat ↓ >30%. Muscle function was preserved. This is the data we needed. 💪 🎯 The big takeaway: Long-term treatment, dose flexibility, and new oral options are shaping the future of obesity care. Personalized = sustainable = best results. #ObesityMedicine #GLP1 #Tirzepatide #Semaglutide #ECO2026 #MedTwitter

@RTVCes IMPRESENTABLE!Este paso atrás!!Anda keno hay cosas que implementar y modifican los que funcionan😤!! Influencias desde alguna perspectiva que se no escapa a los Endocrinólogos( especialistas que asisten a las personas con DM mas evolucionaras / mas complejas. UN PASO ATRÁS 😩😤!!

Los pacientes diabéticos de Canarias están preocupados ante la decisión del Servicio Canario de Salud de dejar de dispensar las tiras reactivas de glucosa en las farmacias.

Hasta que Miguel Bosé no dé su opinión sobre el hantavirus estamos hablando sin saber.

@drfherediaz @JonathanNefro Y GLP1 will be the next one!! Mas Pilates que la mezquita de cordoba 💃💃👏🏻👏🏻👏🏻

Con enfermedad renal crónica tratada con iSGLT2, añadir finerenona, comparado a no hacerlo; se asoció a ↓74% el riesgo de perder >30% de TFGe, mayor beneficio en aquellos que venían con deterioro más rápido. Seguimiento de 18 meses Diabetes Obes Metab 2026 10.1111/dom.70821

These validated, publicly available #polygenic risk scores (PRSs) can improve risk stratification for type 2 #diabetes onset and complications across diverse ancestries, supporting their further evaluation in clinical settings thelancet.com/journals/landi… #T2D #genetics #OpenAccess

Si ves esto en el supermercado: huye. “GLP-1 friendly” en un producto ultraprocesado no significa nada clínicamente. Es marketing puro. Lo que SÍ necesitas si recibes tratamiento con GLP-1: ✅ Proteína en cada comida (1,2-1,5g/kg) ✅ Verdura para llenar el plato ✅ Fibra: fruta, verdura, alimentos integrales, legumbres ✅ Hidratación ✅ Seguimiento especializado Sin olvidarte de entrenar 🏋️!

New @Nature A quintuple [GLP-1 + 4 other] receptor agonist drug that exceeds effects of the dual receptor (GLP-1 and GIP, tirzepatide) in the experimental model vs diabetes and obesity (in case you thought a dual receptor was max effect, as also seen with retatrutide, a triple receptor agonist) nature.com/articles/s4158…

@moreno_perez_o CONGRATS !!! @moreno_perez_o & all ALICANTE TEAM !!! 👏🏻👏🏻. Looks good!🩷

🚨Inpatient safety, effectiveness of SGLT2 inh. and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study 🆓🇪🇸 🏥 979, managed either on oral antidiabetic drugs (with or without insulin) under a start–stop protocol (Group A) or with insulin-only therapy (Group B) 📊 Group A was associated with a ⬇️ 47% risk of severe AE (level 2–3 hypoglycaemia or DKA)(aOR 0.53) and after PS matching (OR 0.31). 📉Group A had a lower median daily glucose level (153 mg/dL vs. 179 mg/dL), lower glycaemic variability and a shorter hospital stay (5 days vs. 7 days) ☠️No differences 🚩What is new? • In hospital non-insulin glucose-lowering therapies reduce hypoglycaemia risk. • Achieve superior glycemic control with reduced variability. • Shorten hospital stay without increased ICU admission or mortality. 🚩How might this study influence clinical practice? Our proof of concept suggests reevaluating standard practices for early in-hospital SGLT2i/GLP-1RA use. 👉🏻evidence supporting a transition from the traditional practice of therapeutic deferral to a more proactive inpatient management strategy 👉🏻hospitalization represents a strategic opportunity to initiate SGLT2 inh. and GLP-1RAs, moving beyond acute stabilization toward the optimization of long-term cardiometabolic care. @isabial_iis @GVAsanitat @BioMedCentral @SpringerNature @diabeteSEEN @SEDiabetes @secardiologia @SENefrologia @Sociedad_SEMI @SEMERGENap @semfyc @fjavesc @cristinatejerap @CristobMorales @DrTinahones @ketandhatariya @ADA_DiabetesPro @EASDnews @EASDelearning @TheAACE @ThaerIdrees @InzucchiSE @AnnePetersMD @EricTopol link.springer.com/content/pdf/10…

🚀 ¡Grandes noticias en la lucha contra la #obesidad! El estudio SYNCHRONIZE-1 de Fase III revela que la survodutida logra una pérdida de peso media del 16,6% (unos 17,8 kg) en 76 semanas en personas con sobrepeso u obesidad.

🔍 ¿Los GLP-1 dañan el nervio óptico? Un metaanálisis de 96.829 participantes en ensayos controlados con placebo de semaglutida y liraglutida acaba de responder: ❌ No hay mayor incidencia de neuropatía óptica isquémica anterior (NAION) con GLP-1 vs. placebo. De hecho, la tasa fue el doble en el grupo placebo (6 vs. 3 casos/100.000 años-persona). Una tranquilidad más para nuestros pacientes. 🧠👁️ 🔗 bjo.bmj.com/content/early/…

In adults with type 2 #diabetes on basal insulin plus modern therapies, real-time #CGM improved glycaemic control versus SMBG during self-management and under clinician-supported management thelancet.com/journals/landi… #T2D #OpenAccess

👩‍⚕️ Los MIR exigen la dimisión de Mónica García larazon.es/sociedad/mir-e…

@albertlecube Endocrinos por el mundo 🥰

Camino a ENDIMET 2026, con ganas de reencontrar buenos amigos y seguir aprendiendo. #ENDIMET2026 Endocrinología en LatinoAmérica.

Summary for patients on GLP-1 drugs and non-drug weight loss re: muscle mass impact @AnnalsofIM acpjournals.org/doi/10.7326/AN…

Time-restricted eating for body weight management in women with polycystic ovary syndrome: a randomized controlled trial “Our results show that in women with PCOS, TRE induced greater weight loss than the controls and was comparable to that achieved with daily CR” nature.com/articles/s4159…

Efficacy & safety of co-administered cagrilintide & semaglutide versus semaglutide alone in adults with #overweight or #obesity with or without type 2 #diabetes in Japan & Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial thelancet.com/journals/landi… .

@ObesitySeen Super!! Cada vez más confianza en este grupo terapéutico 👏🏻. SERÍA bueno analizar calidad de masa ósea ( en la masa muscular , ej estudio semaLEAN, baja volumen de la masa muscular pero no su función ni calidad 👏🏻👏🏻👏🏻) @guillemcuatrec1 @DaniMartinENDO @helejtf @CanariasSocaen

🦴 Semaglutida y salud ósea en personas con obesidad (± DM2): 📊 Nuevos datos sugieren cambios en la masa ósea asociados a la pérdida de peso, sin señal clara de ↑ fracturas. 🔍 Clave: seguimiento a largo plazo 🔗 dom-pubs.onlinelibrary.wiley.com/doi/10.1111/do… @ObesitySEEN